TL1A Inhibitor Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$676M

Range: $359M - $979M

Total Deal Value

$3.5B

Range: $2.2B - $4.9B

Royalty Rate

14.7% - 24.5%

Tiered up to 28.5%

Dev Milestones

$570M

Range: $365M - $777M

Model Your Deal

Market Analysis

TL1A Inhibitor therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 tl1a inhibitor asset in immunology & autoimmune is $676M, with total deal values reaching $3.5B. Development milestones average $570M, while regulatory milestones contribute $997M.

The immunology & autoimmune tl1a inhibitor landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for tl1a inhibitor immunology & autoimmune deals range from 14.7% to 24.5% at the base tier, with tiered escalation reaching 18.7%-28.5% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a tl1a inhibitor immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 tl1a inhibitor licensing deals in immunology & autoimmune average $676M in upfront payments, with a range of $359M to $979M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for tl1a inhibitor immunology & autoimmune transactions?

The median total deal value for Phase 2 tl1a inhibitor assets in immunology & autoimmune is $3.5B, ranging from $2.2B to $4.9B. This includes development milestones ($570M), regulatory milestones ($997M), and commercial milestones ($1.3B).

What royalty rates are standard for tl1a inhibitor deals in immunology & autoimmune?

Base royalty rates for tl1a inhibitor immunology & autoimmune transactions range from 14.7% to 24.5%, with tiered escalations reaching 18.7%-28.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in tl1a inhibitor immunology & autoimmune deals?

TL1A Inhibitor immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($570M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($997M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

TL1A Inhibitor Deal Benchmarks in Immunology & Autoimmune

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Immunology & Autoimmune

Monoclonal Antibody in Immunology & Autoimmune

TL1A Inhibitor in Gastroenterology

Ready to Calculate Your Deal Terms?